HIBSILKO
LIVE

Serial Number

97278212

Owner

Bristol-Myers Squibb Company

Attorney

Xiomara Triana

Filing Date

Feb 22, 2022

Add to watchlist:

No watchlists yet
View on USPTO

HIBSILKO Trademark

Serial Number: 97278212

HIBSILKO is a trademark filed by Bristol-Myers Squibb Company on February 22, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Bristol-Myers Squibb Company (57 trademarks)

Route 206 & Province Line Road
Princeton, NJ 08543

Entity Type: 03

Trademark Details

Filing Date

February 22, 2022

Registration Date

Not Registered

Published for Opposition

April 11, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2026 EXRA
SOU EXTENSION 5 GRANTED
Apr 28, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 28, 2026 AITU
SOU TEAS EXTENSION RECEIVED
Nov 12, 2025 EEXT
SOU EXTENSION 5 FILED
Nov 11, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 4 GRANTED
May 28, 2025 EX4G
SOU EXTENSION 4 FILED
May 28, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
May 28, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 3 GRANTED
Nov 25, 2024 EX3G
SOU EXTENSION 3 FILED
Nov 25, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 25, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 21, 2024 EXRA
SOU EXTENSION 2 GRANTED
May 20, 2024 EX2G
SOU EXTENSION 2 FILED
May 20, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
May 20, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 24, 2023 EXRA
SOU EXTENSION 1 GRANTED
Nov 22, 2023 EX1G
SOU EXTENSION 1 FILED
Nov 22, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 22, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 6, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 11, 2023 NPUB
PUBLISHED FOR OPPOSITION
Apr 11, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 9, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 8, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 8, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 8, 2023 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Sep 29, 2022 GPRN
PRIORITY ACTION E-MAILED
Sep 29, 2022 GPRA
PRIORITY ACTION WRITTEN
Sep 29, 2022 CPRA
ASSIGNED TO EXAMINER
Sep 26, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 28, 2022 NWOS
NEW APPLICATION ENTERED
Feb 25, 2022 NWAP